Mustang Bio Announces First Patient Dosed in Multicenter Phase 1/2 Clinical Trial of MB-102 (CD123-targeted CAR T Cell Therapy) October 1, 2020 - NASDAQ Companies 0 Bay Street News » View More News for October 01, 2020
